Liberty Wealth Management LLC Purchases Shares of 14,786 Edwards Lifesciences Corporation (NYSE:EW)

Key Points

• Liberty Wealth Management LLC acquired 14,786 shares of Edwards Lifesciences, valued at approximately $1,072,000, during the first quarter, as detailed in their recent SEC filing.
• During the same period, several other hedge funds, including North Star Asset Management Inc. and Sound View Wealth Advisors Group LLC, significantly increased their holdings in Edwards Lifesciences, reflecting a growing institutional interest.
• Edwards Lifesciences reported $0.67 earnings per share in its most recent earnings announcement, exceeding analysts' expectations and showing an 11.9% year-over-year revenue increase.

Liberty Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,786 shares of the medical research company's stock, valued at approximately $1,072,000.

Several other hedge funds have also recently modified their holdings of the stock. Sound View Wealth Advisors Group LLC increased its holdings in shares of Edwards Lifesciences by 4.8% during the first quarter. Sound View Wealth Advisors Group LLC now owns 4,914 shares of the medical research company's stock valued at $356,000 after acquiring an additional 223 shares in the last quarter. North Star Asset Management Inc. increased its holdings in shares of Edwards Lifesciences by 34.9% during the first quarter. North Star Asset Management Inc. now owns 47,564 shares of the medical research company's stock valued at $3,447,000 after acquiring an additional 12,293 shares in the last quarter. Wellington Shields & Co. LLC increased its holdings in shares of Edwards Lifesciences by 15.0% during the first quarter. Wellington Shields & Co. LLC now owns 1,150 shares of the medical research company's stock valued at $83,000 after acquiring an additional 150 shares in the last quarter. First National Trust Co increased its holdings in shares of Edwards Lifesciences by 4.9% during the first quarter. First National Trust Co now owns 3,704 shares of the medical research company's stock valued at $268,000 after acquiring an additional 172 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in shares of Edwards Lifesciences by 32.2% during the first quarter. XTX Topco Ltd now owns 27,622 shares of the medical research company's stock valued at $2,002,000 after acquiring an additional 6,722 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.0%

Shares of NYSE:EW opened at $79.30 on Monday. Edwards Lifesciences Corporation has a 1 year low of $59.41 and a 1 year high of $83.00. The firm has a market capitalization of $46.52 billion, a price-to-earnings ratio of 11.41, a price-to-earnings-growth ratio of 3.84 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The business's 50 day moving average price is $76.91 and its 200-day moving average price is $73.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on EW. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Finally, Evercore ISI increased their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of "Moderate Buy" and an average price target of $85.71.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the transaction, the vice president owned 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the transaction, the vice president owned 33,496 shares in the company, valued at $2,514,879.68. The trade was a 4.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,982 shares of company stock worth $2,193,425 in the last ninety days. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.